Increased Serum Endoglin and Transforming Growth Factor β1 mRNA Expression and Risk of Hepatocellular Carcinoma in Cirrhotic Egyptian Patients

  • Teama, Salwa (Department of Clinical Pathology, National Cancer Institute, Cairo University) ;
  • Fawzy, Amal (Department of Molecular Biology, Faculty of Medicine, Ain Shams University) ;
  • Teama, Shirin (Department of Clinical Pathology, Faculty of Medicine, Ain Shams University) ;
  • Helal, Amany (Department of Medical Oncology/Hematology, National Cancer Institute, Cairo University) ;
  • Drwish, Amira Diyaa (Department of Medical Oncology/Hematology, National Cancer Institute, Cairo University) ;
  • Elbaz, Tamer (Department of Endemic Hepatogastroenterology, Cairo University) ;
  • Desouky, Eman (Department of Statistics, National Cancer Institute, Cairo University)
  • Published : 2016.05.01


Transforming growth factor-B1 ($TGF-{\beta}1$ )and its coreceptor endoglin (ENG) have been shown to contribute to hepatocellular tumor development and malignant progression. Our aim was to evaluate the serum expression levels of $ENG/TGF-{\beta}1$ mRNAs and risk of hepatocellular carcinoma in cirrhotic Egyptian patients. Our study included 77 subjects. Real time polymerase chain reaction was used to evaluate the expression level of ENG and $TGF-{\beta}1$mRNAs. The relative expression ratio of ENG mRNA was 0.82 (0.1 -3.2), 0.66 (0.15-5.3), 0.38(0.007-2.8) and 0.12 (0.00-0.22) and the relative expression ratio of $TGF-{\beta}1$mRNA was 1.4 (0.19 -6.2), 1.2 (0.22-4.3), 1.0 (0.15-4.4) and 0.6 (0.00-2.2) for cirrhotic HCC cirrhotic, HCC only and healthy control groups respectively. Increased ENG and $TGF-{\beta}1$ mRNA gene expression was correlated with TNM clinical stage. The expression ratio in TNM stage III-IV 1.1 (0.07-3.2), 1.55 (0.15-6.2) was statistically significantly higher than that in stage I-II 0.47 (0.007-2.8), 1.0 (0.31-4.4) (P<0.05). Our data suggested that increased ENG and $TGF-{\beta}1$ gene expression may participate in hepatocarcinogenesis and increased risk of HCC in individuals with cirrhosis. Early screening for evidence of cirrhosis and consideration of ENG and $TGF-{\beta}1$ as targets for therapy and treatment strategies are warranted.


Endoglin;$TGF{\beta}1$;mRNA;quantitative PCR;hepatocellular carcinoma


  1. Altekruse SF, Mcglynn KA, Reichman ME (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the united states from 1975 to 2005. J Clin Oncol, 27, 1485-91.
  2. Balza E, Castellai P, Zijlstra A, Neri D, Zardil, Siri A (2001). Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer, 94, 579-85.
  3. Barbara NP, wrana JI, letarte M (1999). Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem, 274, 584-94.
  4. Bertolino P, Deckers M, Lebrin F, Ten Dijke P (2005). Transforming growth factor-h signal transduction in angiogenesis and vascular disorders. Chest, 128, 585-90
  5. Bissell DM, Roulet D, George T (2001). Transforming growth factor ${\beta}1$ and the liver. Hepatol, 34, 859-67.
  6. Conley BA, koleva R, Smith JD, Kacer D, Zhang D, Bernabeu C (2004). Endoglin controls cell migration and composition of focal adhesions: function of the cytosolic domain. J Biol Chem, 279, 27440-9.
  7. Derynck R, Akhurst RJ, Balmain A (2001). $TGF{\beta}$ signaling in tumor suppression and cancer progression. Nat Genet, 29, 117-29.
  8. Dong Z, Yao D, Wang Y, et al (2008). Abnormal expression of hepatic transforming growth factor-${\beta}1$ at the early stage of hepatocellular carcinoma formation. J Cancer Mol, 4, 91-6.
  9. El-demerdash T, Abdalla A. (2012). Expression of transforming growth factor ${\beta}1$ gene in patients with hepatocellular carcinoma. Tanta Med Sci J, 1, 68-77.
  10. Elliott RI, Blobe G (2005). Role of transforming growth factor beta in human cancer. J Clin Oncol, 23, 2078-93.
  11. El-zanaty F, Way A (2014). Egypt demographic and health survey 2014. calverton, maryland: ministry of health and population [Arab Republic of Egypt], El-Zanaty and associates, and macro international.
  12. Ferrara N. Review vascular endothelial growth factor: basic science and clinical progress. (2004). Endocr Rev, 25, 581-611.
  13. Flisiak R, Wiercinska-Drapalo A, Tynecka E (2000). Transforming growth factor-beta in pathogenesis of liver diseases. Wiad Lek, 53, 530-7.
  14. Giannelli G, Fransvea E, Marinosci F, et al (2002). Transforming growth factor b1 triggers hepatocellular carcinoma invasavness via ${\alpha}3{\beta}1$ integrin. Am.pathol, 161, 183-93.
  15. Gomez-Esquer F, Agudo D, Martinez-Arribas F, Nunez-villar M and Schneider J (2004). mRNA expression of the angiogenesis markers VEGF and cd105 (endoglin) in human breast cancer. Anticancer Res, 24, 1581-86.
  16. Gordon KJ, Blobe GC (2008). Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta, 1782, 197-228.
  17. Guerrero-esteo M, Sanchez-Elsner T, Jetamendia A, Bernabeu C (2002). Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors i and ii. J Biol Chem, 277, 197-209.
  18. Jakowlew SB (2006). Transforming growth factor-beta in cancer and metastasis. Cancer metastasis Rev, 25, 435-57.
  19. Kim BC, Mamura M, Choi KS, Calabretta B, Kim SJ (2002). Transforming growth factor ${\beta}1$ induces apoptosis through cleavage of bad in a smad3-dependent mechanism in hepatoma cells. Mol Cell Biol, 22, 1369-78.
  20. Kopczynska E, Makarewicz R (2012). Endoglin- a marker of vascular endothelial cell proliferation in cancer. Contemp Oncol, 16, 68-71.
  21. Kumar S, Ghellal A, li C, et al (1999). Breast carcinoma: vascular density determined using cd105 antibody correlates with tumor prognosis. Cancer Res, 59, 856-61.
  22. Lebrin F, Deckersm, Bertolino P, Ten Dijke P (2005). TGF-h receptor functions in the endothelium. Cardiovasc Res, 65, 599-608.
  23. Lebrun (2012). The dual role of $TGF{\beta}1$ in human cancer: from tumor suppression to cancer metastasis. Molecular Biol, 1-28.
  24. Markowitz SD, Roberts AB (1996).Tumor suppressor activity of the tgf-beta pathway in human cancers. Cytokine Growth Factor Rev, 7, 93-102
  25. Perez-Gomez E, Castillo G, Santibanez JF, et al (2010). The role of the tgf-${\beta}$ coreceptor endoglin in cancer. Scientific World J, 10, 2367-84.
  26. Pfaffl MW (2001). A new mathematical model for relative quantification in real-time rt-pcr nucleic acids. Res, 1, 45.
  27. Schimming R, Marme D (2002). Endoglin (CD105) expression in squamous cell carcinoma of the oral cavity. Head neck, 24, 151-56
  28. Shariat SF, kimjh, Andrew B, et al (2001). Preoperative plasma level of transforming growth factor b strongly predict patients outcome in bladder carcinoma. Cancer, 92, 2985-9237.<2985::AID-CNCR10175>3.0.CO;2-5
  29. Sheble N, Hamdy G, Obada MA, Abouria GY, Khalaf F, Khattab E (2013). The value of measurement of circulating tumour cells in hepatocellular carcinoma. Life Sci J, 10, 1-11.
  30. Takahashi N, Kawanishi-tabata R, Haba A, et al (2001). Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res, 7, 52
  31. Thomas MB, JaffeD, Choti MM, et al (2010). Consensus recommendation of the national cancer institute clinical trials, planning meeting. Hepatocellular Carcinoma, 28, 3349-4005.
  32. Wikstrom P, Lissbrant IF, Stattin P, Egevad I, Bergh A (2002). Endoglin (cd105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate, 51, 268-75.
  33. Yagasaki H, Kawata N, Takimoto Y, Nemoto N (2003). Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol, 10, 220-7.